세계의 분자세포 유전학 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 기술별, 제품별, 최종 용도별, 지역별, 부문별 동향(2023-2030년)

Molecular Cytogenetics Market Size, Share & Trends Analysis Report By Application (Oncology, Personalized Medicine), By Technology (FISH, Immunohistochemistry, Karyotyping), By Product, By End-use, By Region, And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,374,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,782,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,597,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

분자세포 유전학 시장 성장 및 동향 :

Grand View Research의 최신 보고서에 따르면, 세계 분자세포 유전학 시장 규모는 2030년까지 44억 6,000만 달러에 달할 것으로 예상됩니다.

이 시장은 2023년부터 2030년까지 10.6%의 CAGR을 나타낼 것으로 예상됩니다. 임상병리 검사에서 분자세포유전학의 보급 증가, 표적 암 치료에 대한 관심 증가, 개인 맞춤형 의료에 대한 관심 증가가 성장을 가속하는 주요 요인으로 작용하고 있습니다. 또한, 유전성 질환의 발병률 증가, 분자세포유전학 분야의 기술 발전, 연구개발 활동의 활성화는 예측 기간 동안 시장 확대를 촉진할 것으로 예상됩니다.

또한, 하이스루풋 시퀀서의 통합을 통해 수행되는 세포유전학 분석도 향후 몇 년동안 성장을 크게 촉진할 것으로 예상되는 요인 중 하나입니다. 많은 과학자와 연구자들이 NGS와 세포유전학 연구소를 통합하고 있으며, 이는 서로 호환됩니다. 이처럼 시퀀싱 가격이 크게 하락하면서 시장은 상당한 속도로 성장할 것으로 추정됩니다.

코로나19는 분자세포유전학 시장에 긍정적인 영향을 미치고 있습니다. 검사 우선순위가 바뀌면서 분자세포유전학 연구소는 코로나19 진단 검사로 방향을 전환했습니다. 또한 공중보건 유전체학에 대한 관심이 높아지면서 집단 기반 유전체 감시 및 질병 전파 추적에 대한 분자세포유전학의 가치가 부각되어 효과적인 공중보건 전략 개발에 기여하고 있습니다. 이와 같이, 팬데믹 상황에서 진단 검사의 높은 발생률은 분자세포 유전학 시장의 성장에 박차를 가하고 있습니다.

다운증후군, 지중해 빈혈, 낭포성 섬유증과 같은 유전성 질환의 발생률 증가는 예측 기간 동안 부문의 성장을 가속할 것으로 예상됩니다. 예를 들어, 세계보건기구(WHO)의 추정에 따르면 1000명 중 약 10명이 유전성 질환을 앓고 있으며, 이는 세계적으로 약 7,000만-8,000만 명에 해당합니다. 또한, 세포 유전학 도구의 기술적 진보에 대한 사업자들의 전략적 이니셔티브가 증가함에 따라 분자세포 유전학 시장이 촉진될 것으로 예상됩니다. 예를 들어, 2022년 10월 Genoox는 Thermo Fisher Scientific과 제휴하여 CytoScan Automated Interpretation and Reporting(AIR) 솔루션을 발표했습니다. 이 도구는 세포유전학 연구 데이터 분석을 용이하게할 것으로 기대됩니다.

분자세포 유전학 시장 보고서 하이라이트

• 용도별로는 암 분야가 2022년 39.70%의 점유율로 시장을 장악했습니다. 이는 CGH 기술이 암 병인에 대한 심층적인 연구를 가능하게 하기 때문입니다.
• 제품별로는 유전자 질환과 개인 맞춤형 의료에 대한 지식과 인식이 높아지면서 소모품이 2022년 39.51%의 점유율을 차지할 것으로 예상됩니다.
• 기술별로는 더 나은 염색체 분석을 위한 기술 발전 증가로 인해 비교 게놈 혼성화 분야가 2022년 분자세포 유전학 시장을 주도할 것으로 보입니다.
• 최종 용도별로는 임상 및 연구실 부문이 2022년 매출 점유율의 대부분을 차지했습니다. 반면, 제약 및 바이오 기업 부문은 예측 기간 동안 가장 빠른 CAGR을 보일 것으로 예상됩니다.
• 2022년 북미는 기술 발전, 의료 인프라 개선, 주요 기업의 존재, 이 지역의 의약품 임상시험 및 승인 건수 증가로 인해 업계를 지배했습니다.

목차

제1장 분자세포 유전학 시장 : 조사 방법과 범위

제2장 분자세포 유전학 시장 : 주요 요약

• 시장 전망
• 용도과 테크놀러지 현황
• 제품과 최종 용도 현황
• 경쟁 구도 현황

제3장 분자세포 유전학 시장 : 시장 변수, 동향 및 범위

• 시장 계통 전망
• 시장 역학
• 업계 분석 툴

제4장 분자세포 유전학 시장 : 용도 비즈니스 분석

• 분자세포 유전학 시장 : 용도 변동 분석
• 유전성 질환
• 종양학
• 맞춤형 의료
• 기타 용도

제5장 분자세포 유전학 시장 : 기술 비즈니스 분석

• 분자세포 유전학 시장 : 기술 변동 분석
• 비교 게놈 하이브리다이제이션
• FISH
• 면역조직화학
• 핵형 분석
• 기타

제6장 분자세포 유전학 시장 : 제품 비즈니스 분석

• 분자세포 유전학 시장 : 제품 변동 분석
• 기기
• 소모품
• 소프트웨어 및 서비스

제7장 분자세포 유전학 시장 : 최종 용도 비즈니스 분석

• 분자세포 유전학 시장 : 최종 용도 변동 분석
• 임상 및 연구기관
• 병원과 Path Labs
• 학술연구기관
• 제약회사 및 바이오테크놀러지 기업
• 기타

제8장 분자세포 유전학 시장 : 지역 비즈니스 분석

• 지역 시장 스냅숏
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 분자세포 유전학 시장 : 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업의 시장 점유율 분석, 2022년
• 기업 개요

제10장 KOL 추천 사항/애널리스트의 견해

LSH

영문 목차

영문목차

Molecular Cytogenetics Market Growth & Trends:

The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 10.6% from 2023 to 2030. Rising penetration of molecular cytogenetics in clinical pathological testing, growing inclination towards targeted cancer treatment, and increasing focus on personalized medicine are the key factors driving growth. In addition, the increasing incidence of genetic disorders, technological advancements in the field of molecular cytogenetics, and rising R&D activities are anticipated to drive market expansion over the forecast period.

Furthermore, the cytogenetic analysis carried out through the integration of high throughput sequencers is another factor that is expected to significantly boost growth in the coming years. A number of scientists and researchers integrate NGS with cytogenetics laboratories as they are compliant with one another. Thus, with a significant drop in sequencing prices, the market is estimated to grow at a substantial pace.

The COVID-19 pandemic has positively impacted the market for molecular cytogenetics. Due to the shift in testing priorities, molecular cytogenetics laboratories were being redirected to conduct COVID-19 diagnostic testing. Furthermore, the increased focus on public health genomics has highlighted the value of molecular cytogenetics in population-based genomic surveillance and tracking disease spread, contributing to the development of effective public health strategies. Thus, the high incidence of diagnostic testing during the pandemic has fueled the growth of the market for molecular cytogenetics.

Increasing incidences of genetic disorders such as Down syndrome, Thalassemia, and Cystic Fibrosis are anticipated to fuel segment growth during the projected timeframe. For instance, according to WHO estimates, about 10 out of every 1000 people are affected with genetic disorders, which is approximately 70-80 million people globally. Moreover, rising strategic initiatives by operating players for technological advancements in cytogenetic tools are projected to propel the market for molecular cytogenetics. For instance, in October 2022, Genoox partnered with Thermo Fisher Scientific to introduce the CytoScan Automated Interpretation and Reporting (AIR) solution. This tool is expected to ease cytogenetic research data analysis.

Molecular Cytogenetics Market Report Highlights:

• Based on application, the oncology segment dominated the market with a share of 39.70% in 2022, due to the capability of the CGH technology to avail detailed studies for cancer etiology
• Based on product, consumables dominated the segment with a share of 39.51% in 2022, owing to the increasing knowledge and awareness regarding genetic diseases and personalized medicines
• Based on technology, the comparative genomic hybridization segment dominated the market for molecular cytogenetics in 2022 due to the rising technological advancements for better chromosomal analysis
• Based on end-use, the clinical & research laboratories segment held a majority of the revenue share in 2022. On the other hand, the pharmaceutical & biotech companies segment is anticipated to witness the fastest CAGR over the forecast period
• In 2022, North America dominated the industry owing to the rising technological advancements, improving healthcare infrastructure, the presence of major players, and the increasing number of drug trials and their approvals in the region

Table of Contents

Chapter 1 Molecular Cytogenetics Market: Research Methodology And Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Technology Segment
    • 1.1.1.3 Product Segment
    • 1.1.1.4 End Use Segment
• 1.2 Regional Scope
• 1.3 Estimates and Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Molecular Cytogenetics Market: Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Technology Snapshot
• 2.3 Product And End Use Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Molecular Cytogenetics Market: Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Related/Ancillary Market Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Drivers Analysis
    • 3.2.1.1 Rapid technological advancements
    • 3.2.1.2 Increasing prevalence of genetic disorders
    • 3.2.1.3 Growing application in oncology
    • 3.2.1.4 Increasing demand for personalized medicine
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 High Costs Of Testing
    • 3.2.2.2 Lack Of Reimbursement Policies
• 3.3 Industry Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Pestel Analysis

Chapter 4 Molecular Cytogenetics Market: Application Business Analysis

• 4.1 Molecular Cytogenetics Market: Application Movement Analysis
• 4.2 Genetic Disorders
  • 4.2.1 Genetic Disorders Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.3 Oncology
  • 4.3.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.4 Personalized Medicine
  • 4.4.1 Personalized Medicine Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.5 Other Application
  • 4.5.1 Other Application Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Molecular Cytogenetics Market: Technology Business Analysis

• 5.1 Molecular Cytogenetics Market: Technology Movement Analysis
• 5.2 Comparative Genomic Hybridisation
  • 5.2.1 Comparative Genomic Hybridisation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.2.2 ACGH
    • 5.2.2.1 ACGH Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.2.3 SCGH
    • 5.2.3.1 SCGH Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.3 Fish
  • 5.3.1 Fish Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.4 Immunohistochemistry
  • 5.4.1 Immunohistochemistry Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.5 Karyotyping
  • 5.5.1 Karyotyping Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.5.2 Spectral
    • 5.5.2.1 Spectral Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.5.3 Virtual
    • 5.5.3.1 Virtual Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6 Others
  • 5.6.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Molecular Cytogenetics Market: Product Business Analysis

• 6.1 Molecular Cytogenetics Market: Product Movement Analysis
• 6.2 Instruments
  • 6.2.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.3 Consumables
  • 6.3.1 Consumables Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.4 Software & Services
  • 6.4.1 Software & Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Molecular Cytogenetics Market: End Use Business Analysis

• 7.1 Molecular Cytogenetics Market: End Use Movement Analysis
• 7.2 Clinical & Research Laboratories
  • 7.2.1 Clinical & Research Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.3 Hospitals & Path Labs
  • 7.3.1 Hospitals & Path Labs Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.4 Academic Research Institutes
  • 7.4.1 Academic Research Institutes Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.5 Pharmaceutical & Biotech Companies
  • 7.5.1 Pharmaceutical & Biotech Companies Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6 Others
  • 7.6.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Molecular Cytogenetics Market: Regional Business Analysis

• 8.1 Regional Market Snapshot
• 8.2 North America
  • 8.2.1 North America Molecular Cytogenetics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.2.1 U.S. Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.2.2.2 Key Country Dynamics
    • 8.2.2.3 Regulatory Framework
    • 8.2.2.4 Reimbursement Scenario
  • 8.2.3 Canada
    • 8.2.3.1 Canada Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.2.3.2 Key Country Dynamics
    • 8.2.3.3 Regulatory Framework
    • 8.2.3.4 Reimbursement Scenario
• 8.3 Europe
  • 8.3.1 Europe Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
  • 8.3.2 UK
    • 8.3.2.1 UK Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.2.2 Key Country Dynamics
    • 8.3.2.3 Regulatory Framework
    • 8.3.2.4 Reimbursement Scenario
  • 8.3.3 Germany
    • 8.3.3.1 Germany Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.3.2 Key Country Dynamics
    • 8.3.3.3 Regulatory Framework
    • 8.3.3.4 Reimbursement Scenario
  • 8.3.4 Spain
    • 8.3.4.1 Spain Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.4.2 Key Country Dynamics
    • 8.3.4.3 Regulatory Framework
    • 8.3.4.4 Reimbursement Scenario
  • 8.3.5 France
    • 8.3.5.1 France Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.5.2 Key Country Dynamics
    • 8.3.5.3 Regulatory Framework
    • 8.3.5.4 Reimbursement Scenario
  • 8.3.6 Italy
    • 8.3.6.1 Italy Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.6.2 Key Country Dynamics
    • 8.3.6.3 Regulatory Framework
    • 8.3.6.4 Reimbursement Scenario
  • 8.3.7 Denmark
    • 8.3.7.1 Denmark Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.7.2 Key Country Dynamics
    • 8.3.7.3 Regulatory Framework
    • 8.3.7.4 Reimbursement Scenario
  • 8.3.8 Sweden
    • 8.3.8.1 Sweden Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.8.2 Key Country Dynamics
    • 8.3.8.3 Regulatory Framework
    • 8.3.8.4 Reimbursement Scenario
  • 8.3.9 Norway
    • 8.3.9.1 Norway Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.3.9.2 Key Country Dynamics
    • 8.3.9.3 Regulatory Framework
    • 8.3.9.4 Reimbursement Scenario
• 8.4 Asia Pacific
  • 8.4.1 Asia-Pacific Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
  • 8.4.2 Japan
    • 8.4.2.1 Japan Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.4.2.2 Key Country Dynamics
    • 8.4.2.3 Regulatory Framework
    • 8.4.2.4 Reimbursement Scenario
  • 8.4.3 China
    • 8.4.3.1 China Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.4.3.2 Key Country Dynamics
    • 8.4.3.3 Regulatory Framework
    • 8.4.3.4 Reimbursement Scenario
  • 8.4.4 India
    • 8.4.4.1 India Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.4.4.2 Key Country Dynamics
    • 8.4.4.3 Regulatory Framework
    • 8.4.4.4 Reimbursement Scenario
  • 8.4.5 South Korea
    • 8.4.5.1 South Korea Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.4.5.2 Key Country Dynamics
    • 8.4.5.3 Regulatory Framework
    • 8.4.5.4 Reimbursement Scenario
  • 8.4.6 Thailand
    • 8.4.6.1 Thailand Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.4.6.2 Key Country Dynamics
    • 8.4.6.3 Regulatory Framework
    • 8.4.6.4 Reimbursement Scenario
  • 8.4.7 Australia
    • 8.4.7.1 Australia Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.4.7.2 Key Country Dynamics
    • 8.4.7.3 Regulatory Framework
    • 8.4.7.4 Reimbursement Scenario
• 8.5 Latin America
  • 8.5.1 Latin America Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Brazil Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.5.2.2 Key Country Dynamics
    • 8.5.2.3 Regulatory Framework
    • 8.5.2.4 Reimbursement Scenario
  • 8.5.3 Mexico
    • 8.5.3.1 Mexico Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.5.3.2 Key Country Dynamics
    • 8.5.3.3 Regulatory Framework
    • 8.5.2.4 Reimbursement Scenario
  • 8.5.4 Argentina
    • 8.5.4.1 Argentina Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.5.4.2 Key Country Dynamics
    • 8.5.4.3 Regulatory Framework
    • 8.5.4.4 Reimbursement Scenario
• 8.6 MEA
  • 8.6.1 MEA Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.2.1 South Africa Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.6.2.2 Key Country Dynamics
    • 8.6.2.3 Regulatory Framework
    • 8.6.2.4 Reimbursement Scenario
  • 8.6.3 Saudi Arabia
    • 8.6.3.1 Saudi Arabia Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.6.3.2 Key Country Dynamics
    • 8.6.3.3 Regulatory Framework
    • 8.6.3.4 Reimbursement Scenario
  • 8.6.4 UAE
    • 8.6.4.1 UAE Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.6.4.2 Key Country Dynamics
    • 8.6.4.3 Regulatory Framework
    • 8.6.2.4 Reimbursement Scenario
  • 8.6.5 Kuwait
    • 8.6.5.1 Kuwait Molecular Cytogenetics Market, 2018 - 2030 (USD Million)
    • 8.6.5.2 Key Country Dynamics
    • 8.6.5.3 Regulatory Framework
    • 8.6.5.4 Reimbursement Scenario

Chapter 9 Molecular Cytogenetics Market: Competitive Landscape

• 9.1 Company Categorization
• 9.2 Strategy Mapping
  • 9.2.1 New product launch
  • 9.2.2 Partnerships
  • 9.2.3 Acquisition
  • 9.2.4 Collaboration
  • 9.2.5 Funding
• 9.3 Company Market Share Analysis, 2022
• 9.4 Company Profiles
  • 9.4.1 BIOVIEW
    • 9.4.1.1 Company overview
    • 9.4.1.2 Financial performance
    • 9.4.1.3 Product benchmarking
    • 9.4.1.4 Strategic initiatives
  • 9.4.2 DANAHER
    • 9.4.2.1 Company overview
    • 9.4.2.1.1 Leica Biosystems Nussloch GmbH
    • 9.4.2.2 Financial performance
    • 9.4.2.3 Product benchmarking
    • 9.4.2.4 Strategic initiatives
  • 9.4.3 METASYSTEMS
    • 9.4.3.1 Company overview
    • 9.4.3.2 Financial performance
    • 9.4.3.3 Product benchmarking
    • 9.4.3.4 Strategic initiatives
  • 9.4.4 AGILENT TECHNOLOGIES, INC.
    • 9.4.4.1 Company overview
    • 9.4.4.2 Financial performance
    • 9.4.4.3 Product benchmarking
    • 9.4.4.4 Strategic initiatives
  • 9.4.5 ABBOTT
    • 9.4.5.1 Company overview
    • 9.4.5.2 Financial performance
    • 9.4.5.3 Product benchmarking
    • 9.4.5.4 Strategic initiatives
  • 9.4.6 BIO-RAD LABORATORIES, INC.
    • 9.4.6.1 Company overview
    • 9.4.6.2 Financial performance
    • 9.4.6.3 Product benchmarking
    • 9.4.6.4 Strategic initiatives
  • 9.4.7 ILLUMINA, INC.
    • 9.4.7.1 Company overview
    • 9.4.7.2 Financial performance
    • 9.4.7.3 Product benchmarking
    • 9.4.7.4 Strategic initiatives
  • 9.4.8 OXFORD GENE TECHNOLOGY
    • 9.4.8.1 Company overview
    • 9.4.8.2 Financial performance
    • 9.4.8.3 Product benchmarking
    • 9.4.8.4 Strategic initiatives
  • 9.4.9 F. HOFFMANN-LA ROCHE LTD
    • 9.4.9.1 Company overview
    • 9.4.9.1.1 Genentech, Inc.
    • 9.4.9.2 Financial performance
    • 9.4.9.4 Product benchmarking
    • 9.4.9.5 Strategic initiatives
  • 9.4.10 PERKINELMER INC.
    • 9.4.10.1 Company overview
    • 9.4.10.2 Financial performance
    • 9.4.10.3 Product benchmarking
    • 9.4.10.4 Strategic initiatives
  • 9.4.11 QUEST DIAGNOSTICS INCORPORATED
    • 9.4.11.1 Company overview
    • 9.4.11.1.1 Sonora Quest Laboratories
    • 9.4.11.2 Financial performance
    • 9.4.11.3 Product benchmarking
    • 9.4.11.4 Product benchmarking
    • 9.4.11.5 Strategic initiatives
  • 9.4.12 APPLIED SPECTRAL IMAGING
    • 9.4.12.1 Company overview
    • 9.4.12.2 Financial performance
    • 9.4.12.3 Product benchmarking
    • 9.4.12.4 Strategic initiatives
  • 9.4.13 BIOLOGICAL INDUSTRIES USA, INC.
    • 9.4.13.1 Company overview
    • 9.4.13.2 Financial performance
    • 9.4.13.3 Product benchmarking
    • 9.4.13.4 Strategic initiatives
  • 9.4.14 CYTOTEST
    • 9.4.14.1 Company overview
    • 9.4.14.2 Financial performance
    • 9.4.14.3 Product benchmarking
    • 9.4.14.4 Strategic initiatives
  • 9.4.15 CYTOGNOMIX
    • 9.4.15.1 Company overview
    • 9.4.15.2 Financial performance
    • 9.4.15.3 Product benchmarking
  • 9.4.16 GENIAL GENETICS
    • 9.4.16.1 Company overview
    • 9.4.16.2 Financial performance
    • 9.4.16.3 Product benchmarking
    • 9.4.16.4 Strategic initiatives
  • 9.4.17 DIAGNOSTIC CYTOGENETICS, INC. (DCI)
    • 8.4.17.1 Company overview
    • 8.4.17.2 Financial performance
    • 8.4.17.3 Product benchmarking

Chapter 10 KOL Recommendations/Analyst Perspective

관련자료